Logo

Plus Therapeutics’ Rhenium (186Re) Obisbemeda Received the US FDA’s Orphan Drug Designation to Treat Breast Cancer with Leptomeningeal Metastases

Share this
Plus Therapeutics

Plus Therapeutics’ Rhenium (186Re) Obisbemeda Received the US FDA’s Orphan Drug Designation to Treat Breast Cancer with Leptomeningeal Metastases

Shots:

  • The ODD for was granted based on the results from the dose escalation part of the P-I/IIa (ReSPECT-LM) trial evaluating the MTD/MFD, safety & efficacy Rhenium (186Re) in patients with leptomeningeal metastases & post receiving FTD by the UD FDA
  • As per the results of Cohort 1-3 from the P-I portion of the trial, the CNS tumour cell count at day 28 in the 10 evaluable patients was reduced by ~53%. Additionally, Cohort 4 patient intake has been completed, and Cohort 5 enrollment is scheduled to start by EY 2023 following a standard safety evaluation
  • Trial updates are to be reported at SNO 2023. Additionally, the company is also evaluating Rhenium (186Re) in a P-I/II (ReSPECT-GBM trial) for recurrent glioma patients

Ref: Globenewswire | Image: Plus Therapeutics

Related News:- Plus Therapeutics Reports First Patient Dosing in P-I/IIa (ReSPECT-LM) Dose Escalation Trial of 186RNL for Leptomeningeal Metastases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions